Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose-regimen exploration study of HW211026 ointment for actinic keratosis
CTR20262631Phase 2Active
- Sponsor
- Humanwell Innovative Drug R&D Center
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HW211026 in actinic keratosis (AK), sponsored by Humanwell Innovative Drug R&D Center. Started Aug 2026; status: active.
02
Drugs
HW211026
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on CTR20262631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262631.